论文部分内容阅读
目的:对上海、北京和石家庄三城市应用α-2b干扰素治疗慢性丙型肝炎做经济学评价.方法:根据对三城市的部分慢性丙肝、代偿性肝硬化、失代偿性肝硬化病人调查所得的门诊费用、住院费用.并根据慢性丙型肝炎的自然史和α-2b干扰素的治疗效果,预测并比较α-2b干扰素治疗组和常规治疗组的慢性丙肝病人在30a内的有关费用和预后,并进行成本-效益和成本-效果分析.结果:治疗后30a内,α-2b干扰素治疗组比常规治疗组增加852个存活人年和1487个生命质量调整年.α-2b干扰素治疗组比常规治疗组节省医疗费用29459371元,效益-成本比值为1.32.α-2b干扰素治疗组比常规治疗组每增加一个生命年所节省的费用为8321元,每增加一个生命质量调整年所节省的费用为4768元.结论:应用α-2b干扰素治疗慢性丙型肝炎可取得较好的临床和经济学结果.
Objective: To evaluate the economic evaluation of interferon α-2b in chronic hepatitis C patients in Shanghai, Beijing and Shijiazhuang, three cities.Methods: According to the economic evaluation of partial chronic hepatitis C, compensatory cirrhosis and decompensated cirrhosis in three cities, Survey outpatient costs, hospitalization costs.According to the natural history of chronic hepatitis C and the therapeutic effect of interferon alfa-2b, predict and compare the α-2b interferon treatment group and the conventional treatment group of chronic hepatitis C patients within 30a Cost-effectiveness and cost-effectiveness analysis.Results: Within 30a after treatment, α2b interferon treatment group than the conventional treatment group increased by 852 survival years and 1487 quality of life adjustment year.α- 2b interferon treatment group than the conventional treatment group to save medical costs 29459371 yuan, benefit-cost ratio of 1.32.α-2b interferon treatment group than the conventional treatment group for each additional life cost savings of 8321 yuan for each additional life Quality-adjusted annual savings of 4768 yuan.Conclusion: α-2b interferon treatment of chronic hepatitis C can get better clinical and economic results.